Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $11.00.
AQST has been the subject of a number of research reports. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective for the company. Leerink Partners lifted their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. JMP Securities restated a "market outperform" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th.
Get Our Latest Research Report on Aquestive Therapeutics
Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $594,000. Rhumbline Advisers acquired a new position in Aquestive Therapeutics during the 2nd quarter valued at $254,000. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics in the 2nd quarter worth $27,000. Marshall Wace LLP bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $200,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics during the second quarter valued at about $380,000. Institutional investors own 32.45% of the company's stock.
Shares of Aquestive Therapeutics stock opened at $3.10 on Wednesday. Aquestive Therapeutics has a 1 year low of $2.24 and a 1 year high of $6.23. The stock has a 50-day moving average price of $3.97 and a 200 day moving average price of $4.16. The company has a market cap of $282.66 million, a P/E ratio of -6.89 and a beta of 2.71.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analysts' expectations of $12.69 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. On average, equities analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.